Home Health New drug shows promise dog dementia

New drug shows promise dog dementia

About 40% of dogs over the age of 12 will develop a certain level of canine cognitive dysfunction, also known as canine dementia. A pilot clinical study conducted for dogs with CCD has examined the drug Ropesalazine, which is a candidate for the treatment of patients with human Alzheimer's.

According to the manufacturer of the drug, GNT Pharma, based on South Korea, Ropesalazine has shown efficacy in patients with canine dementia, returning to normal cognitive function and daily activity after eight weeks of treatment.

Thumbnail: Photography © CatLane | Getty Images.

About the author

Jackie Brown is a freelance Southern California writer specializing in the pet industry. Reach it on jackiebrownwriter.wordpress.com.

Editor's Note: This article appeared in the Dogster magazine. Have you seen the new Dogster magazine in stores? Or in the waiting room of your vet's office? Sign up now to receive the Dogster magazine directly to you!

More information on the health and care of dogs on Dogster.com:

Must Read

Social protection. The explosive tracks of the Medef on pensions

French retirement, the employers never wanted it. This system of distribution, based on solidarity, financed by a levy on the wealth created, causes the...

Notes draft: Introduction of Alondes Williams and other JuCo stars

1 Introduction. The JuCo Player: A much overlooked type of player because great NBA types only get through occasionally. Of course it is often...

Europa League reaction: Arsenal and Chelsea reach semi-finals, plus Man Utd news conference – Live

Europa League reaction: Arsenal and Chelsea reach semi-finals, plus Man Utd news conference - Live - BBC Sport